ライフサイエンスコーパス: be noninferior to

1 zolid (200 mg once daily) has been proven to be noninferior to 10 days of linezolid (600 mg twice dai

2 tedizolid phosphate (plus 4 days of placebo) was noninferior to 10 days of 600-mg twice-daily oral li

3 d sinogram-affirmed iterative reconstruction was noninferior to 100% exposure (P = .002 and P < .001,

4 tents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without signific

5 -day treatment with systemic glucocorticoids was noninferior to 14-day treatment with regard to reexa

6 latelet treatment with DAPT for 6 months may be noninferior to 24-month DAPT in aspirin-sensitive pat

7 3D in women aged 15-25 years and 2D (M0,12) was noninferior to 2D (M0,6).

8 After BEACOPPbaseline, 20 Gy IF-RT was noninferior to 30 Gy (10-year PFS, 84% v 84%; HR, 1.

9 e, both 2D regimens in girls aged 9-14 years were noninferior to 3D in women aged 15-25 years and 2D

10 12) elicited HPV-16/18 immune responses that were noninferior to 3D in women aged 15-25 years.

11 Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering th

12 nclusion: Our data suggest that (18)F-DCFPyL is noninferior to (68)Ga-PSMA-HBED-CC, while offering th

13 A single 1200-mg dose of oritavancin was noninferior to 7-10 days of vancomycin in treating A

14 hs of once-weekly rifapentine plus isoniazid was noninferior to 9 months of isoniazid alone for preve

15 resorbable scaffold has been demonstrated to be noninferior to a contemporary metallic drug-eluting s

16 A single 1500-mg infusion of dalbavancin is noninferior to a 2-dose regimen, has a similar safety

17 Dalbavancin delivered as a single dose was noninferior to a 2-dose regimen (81.4% vs 84.2%; dif

18 es with about 5 hours of therapeutic contact was noninferior to a conventional course of CBT that pro

19 tive strategy regarding red-cell transfusion was noninferior to a liberal strategy with respect to th

20 To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macul

21 ge from baseline (letters) with brolucizumab was noninferior to aflibercept at week 12 (5.75 and 6.89

22 nal vein occlusion, intravitreal bevacizumab was noninferior to aflibercept with respect to visual ac

23 of less than 1.3 indicating that SLND alone is noninferior to ALND.

24 icardial, centrifugal-flow LVAD was found to be noninferior to an axial-flow LVAD with respect to sur

25 me, an iFR-guided revascularization strategy was noninferior to an FFR-guided revascularization strat

26 xtended prophylaxis for 28 days with aspirin was noninferior to and as safe as dalteparin for the pre

27 High-dose unilateral ECT was noninferior to bitemporal ECT regarding the 24-item

28 that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight hep

29 sessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the

30 Trials concluding IAD is noninferior to CAD were based on wide NIMs that inclu

31 Here, we evaluated whether TCC is noninferior to CBT-I for the treatment of insomnia in

32 Tests of noninferiority showed that TCC was noninferior to CBT-I at 15 months ( P = .02) and at

33 CCTA/rCTP is noninferior to CCTA/SPECT-MPI to discriminate ACS and

34 horacic echocardiography and lung ultrasound are noninferior to chest x-ray for screening of pneumoth

35 horacic echocardiography and lung ultrasound is noninferior to chest radiograph when used to accurate

36 venous catheters coated with 5-fluorouracil were noninferior to chlorhexidine and silver sulfadiazin

37 care is not available leads to outcomes that are noninferior to CIC follow-up.

38 Etelcalcetide was noninferior to cinacalcet on the primary end point.

39 The hypothesis that cefpodoxime would be noninferior to ciprofloxacin by a 10% margin (ie, for

40 er mindfulness-based stress reduction (MBSR) is noninferior to cognitive behavioral therapy for insom

41 The short-course radiotherapy was noninferior to commonly used radiotherapy.

42 ositioned, continuous-flow, centrifugal pump was noninferior to contemporaneously implanted, commerci

43 Intermittent androgen deprivation was noninferior to continuous therapy with respect to ov

44 were to assess whether intermittent therapy was noninferior to continuous therapy with respect to su

45 ssant prescribing in the DEV and IMCP groups was noninferior to control (mean percentage point differ

46 ach trial, we tested whether dexmedetomidine was noninferior to control with respect to proportion of

47 te symptomatic VTE, NOACs have been shown to be noninferior to conventional anticoagulant therapy for

48 ty and specificity of CellScope-based LED FM was noninferior to conventional LED FM by using a presel

49 Filtered sunlight was noninferior to conventional phototherapy for the tre

50 Apixaban was noninferior to conventional therapy (P<0.001) for pr

51 A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatmen

52 ed to achieve noninferiority at 6 months but was noninferior to CPVI at 1 year in achieving freedom o

53 single procedure but, after redo procedures, was noninferior to CPVI at 12 months for freedom from AF

54 Two randomized trials revealed rituximab to be noninferior to cyclophosphamide for inducing remissio

55 MMF is likely to be noninferior to cyclophosphamide for the induction of

56 ies and at both starting doses, peginesatide was noninferior to darbepoetin in increasing and maintai

57 ction of XG-102 at the end of ocular surgery is noninferior to dexamethasone eye drops in the treatme

58 anterior cell grades for both XG-102 groups were noninferior to dexamethasone (-0.054 anterior cell

59 Self-administered therapy without reminders was noninferior to direct observation in the United Stat

60 mpared these 2 stents and has shown that ZES was noninferior to EES at 12-month for the primary end p

61 e gene expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 months post tran

62 Stenting was noninferior to endarterectomy with regard to the pri

63 gh risk for surgical complications, stenting was noninferior to endarterectomy with regard to the rat

64 In acutely ill medical patients, rivaroxaban was noninferior to enoxaparin for standard-duration thro

65 ERALD 1 and 725 from EMERALD 2, peginesatide was noninferior to epoetin in maintaining hemoglobin lev

66 ive Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients wi

67 pt and methotrexate, P=0.26); triple therapy was noninferior to etanercept and methotrexate, since th

68 nd hydroxychloroquine added to methotrexate, was noninferior to etanercept plus methotrexate in patie

69 paclitaxel-eluting stents were not shown to be noninferior to everolimus-eluting stents, and they re

70 d on a phase 3 trial, telaprevir twice daily is noninferior to every 8 hours in producing SVR12, with

71 nstruction at 25% and 50% exposure reduction was noninferior to FBP at 100% exposure (P </= .013).

72 is using mixed linear models showed that PBT was noninferior to FBT on all outcomes at 6-, 12-, and 1

73 Although withholding FDP was found to be noninferior to FDP for the study population as a whol

74 Withholding FDP was noninferior to FDP in holes </=400 mum in diameter.

75 We aimed to evaluate whether iFR is noninferior to FFR with respect to the rate of subseq

76 Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasi

77 XELOX is noninferior to FOLFOX-4 as a first-line treatment for

78 igh risk for cardiovascular events, degludec was noninferior to glargine with respect to the incidenc

79 Group 2 was noninferior to group 1 for the ACR50 response at wee

80 ring a mean follow-up of 2.3 years, Respimat was noninferior to HandiHaler with respect to the risk o

81 b/IIIa (Gp IIb/IIIa) inhibition was found to be noninferior to heparin plus planned Gp IIb/IIIa block

82 e daily after initial treatment with heparin was noninferior to high-quality standard therapy and cau

83 At moderate doses, celecoxib was found to be noninferior to ibuprofen or naproxen with regard to c

84 erm effectiveness of home-based HT with a CD is noninferior to iHT performed by therapists in pediatr

85 ment Therapy (ENCORE), at 1 year, eliglustat was noninferior to imiglucerase enzyme therapy in mainta

86 t the 1-year follow-up, telephone counseling was noninferior to in-person counseling for all psychoso

87 phone delivery of BRCA1/2 genetic counseling was noninferior to in-person delivery.

88 the hypothesis that intramuscular midazolam was noninferior to intravenous lorazepam by a margin of

89 Intravenous-to-oral solithromycin was noninferior to intravenous-to-oral moxifloxacin.

90 d to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment

91 d to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment

92 imited evidence that the Watchman device may be noninferior to long-term OAC in selected patients.

93 >/=1, a left atrial appendage closure device is noninferior to long-term warfarin for stroke preventi

94 Sulfur hexafluoride gas was found to be noninferior to longer-acting gases (95% confidence in

95 Sulfur hexafluoride gas tamponade was noninferior to longer-acting gases in the surgical m

96 objective was to determine whether aliskiren was noninferior to losartan in reducing LV mass index fr

97 that femoral hemostasis achieved through VCD is noninferior to manual compression in terms of vascula

98 oing transfemoral coronary angiography, VCDs were noninferior to manual compression in terms of vascu

99 Pyronaridine-artesunate was noninferior to mefloquine plus artesunate for the pr

100 Miltefosine is noninferior to meglumine antimoniate for treatment of

101 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all primary analysis

102 th ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult patients with cIAI

103 Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primary (83.0% [323/

104 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatment of complic

105 Everolimus 1.5 mg was noninferior to MMF for this endpoint at month 12 (35

106 owance for as-needed ranibizumab injections, was noninferior to monthly ranibizumab as well as to as-

107 nd in eyes with PVD, and quarterly treatment was noninferior to monthly treatment (P = 0.001).

108 wed that zoledronic acid (ZA) every 3 months was noninferior to monthly ZA in reducing the risks of S

109 howed that monthly and bimonthly aflibercept were noninferior to monthly ranibizumab at preventing vi

110 Glycerol phenylbutyrate was noninferior to NaPBA with respect to ammonia control

111 The use of HHHFNC was noninferior to nCPAP with regard to the primary outc

112 test if high-flow conditioned oxygen therapy is noninferior to NIV for preventing postextubation resp

113 h ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 y

114 and 10-mg daily doses of ulipristal acetate were noninferior to once-monthly leuprolide acetate in c

115 ectomy to date, and it demonstrates that RPD is noninferior to OPD in terms of pancreatic fistula dev

116 s demonstrated that high flow nasal cannulae are noninferior to or no better than CPAP when used to s

117 , -0.85% to -0.62%] for DPP4 inhibitors) and were noninferior to other hypoglycemic agents.

118 ed with sentinel lymph node dissection alone was noninferior to overall survival for those treated wi

119 at hospitals without on-site cardiac surgery was noninferior to PCI performed at hospitals with on-si

120 procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molec

121 (n = 773) or PES (n = 775), at 9 months, ZES was noninferior to PES with rates of target vessel failu

122 ngle-photon emission tomography was found to be noninferior to PET in terms of specificity (P < .001)

123 It was hypothesized that PF tafluprost would be noninferior to PF timolol over 12 weeks with regard t

124 We hypothesized that semaglutide would be noninferior to placebo for the primary outcome.

125 The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and sec

126 rimary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary out

127 t exenatide, administered once weekly, would be noninferior to placebo with respect to safety and sup

128 Sitagliptin was noninferior to placebo for the primary composite car

129 ng that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P<0.0

130 To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1

131 Primary analyses examined whether 4F-PCC was noninferior to plasma for the coprimary end points o

132 5 mg in low-body-weight (LBW) patients would be noninferior to prasugrel 10 mg in higher-body-weight

133 vant chemotherapy and interval cytoreduction are noninferior to primary cytoreduction and adjuvant ch

134 sachusetts without on-site surgical services were noninferior to procedures performed at hospitals wi

135 To determine whether yoga is noninferior to PT for cLBP.

136 manualized yoga program for nonspecific cLBP was noninferior to PT for function and pain.

137 BR was noninferior to R-CHOP/R-CVP, as assessed by the prim

138 al to determine whether cryoballoon ablation was noninferior to radiofrequency ablation in symptomati

139 this randomized trial, cryoballoon ablation was noninferior to radiofrequency ablation with respect

140 In the per protocol analysis, bevacizumab was noninferior to ranibizumab (bevacizumab minus ranibi

141 Bevacizumab was noninferior to ranibizumab for visual acuity at 1 ye

142 Ranibizumab with laser was noninferior to ranibizumab monotherapy (mean average

143 3 mm [-19, -7], P < 0.001, respectively) and were noninferior to rofecoxib (-2 mm [-8, 4], P < 0.001

144 ponses to routine vaccines given with 4CMenB were noninferior to routine vaccines alone for all antig

145 lower-dose FBP images without ANLM or SAFIRE were noninferior to routine-dose images for abdominal CT

146 COBI was noninferior to RTV in combination with ATV plus FTC/

147 multicenter AMI trial, second-generation EES was noninferior to SES, and superiority for MACE was sug

148 osbuvir-velpatasvir-voxilaprevir for 8 weeks was noninferior to sofosbuvir-velpatasvir for 12 weeks,

149 Primary care management was noninferior to specialist management with a mean cha

150 Low dose is noninferior to standard dose with respect to rate of

151 These data indicate BR is noninferior to standard therapy with regard to clinic

152 ngle-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in pre

153 Micafungin was noninferior to standard care as antifungal prophylax

154 Rivaroxaban was noninferior to standard therapy (noninferiority marg

155 A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and

156 four sites in Italy tested whether rituximab is noninferior to steroids in maintaining remission in j

157 In conclusion, rituximab was noninferior to steroids for the treatment of juvenil

158 rical treatment with beta-lactam monotherapy was noninferior to strategies with a beta-lactam-macroli

159 Oral edoxaban was noninferior to subcutaneous dalteparin with respect

160 Pazopanib was noninferior to sunitinib with respect to progression

161 l" strategy of left atrial appendage closure is noninferior to "systemic" anticoagulation with warfar

162 The TAXUS Element was noninferior to TAXUS Express with respect to both th

163 , -4.9% to 12.0%), so telaprevir twice daily is noninferior to telaprevir every 8 hours.

164 e immunogenicity of CCIV was demonstrated to be noninferior to that of TIV on the basis of the ratio

165 t material-enhanced computed tomography (CT) is noninferior to that of a traditional 13-hour oral reg

166 corneal donor tissue preserved 8 to 14 days is noninferior to that of donor tissue preserved 7 days

167 ithout axillary lymph node dissection (ALND) is noninferior to that of women treated with axillary di

168 ibody response to HPV-6, 11, 16, and 18 that was noninferior to that generated by the qHPV vaccine.

169 e-day IOP-lowering efficacy of BAK-free TRAV was noninferior to that of BAK 0.02%-preserved BIM; both

170 The rate of response in group 2 was noninferior to that of group 1.

171 The EFS for SR patients in AAML0631 was noninferior to that of patients in the AIDA 0493 his

172 The IOP-lowering effect of PF tafluprost was noninferior to that of PF timolol.

173 sis found that the efficacy of isavuconazole was noninferior to that of voriconazole.

174 at outcomes of patients followed in the TMVC are noninferior to the CIC.

175 onths; 0, 6, 12 months; or 0, 12, 24 months) are noninferior to the standard schedule at >2 years aft

176 apy with ceftaroline fosamil was observed to be noninferior to the comparator agents (ceftriaxone for

177 three lower-dose alternatives were found to be noninferior to the routine-dose FBP.

178 At 2-year follow-up, the EES was found to be noninferior to the SES with regard to both patient-re

179 The everolimus-eluting stent was found to be noninferior to the sirolimus-eluting stent.

180 We hypothesized that VO training would be noninferior to the VSI approach with respect to chest

181 Assessment of LV function with SSIR at 3.0 T is noninferior to the standard of reference irrespective

182 operative urine output target of 0.2 mL/kg/h is noninferior to the standard target of 0.5 mL/kg/h and

183 95% confidence interval: 0.8%, 5.7%), which was noninferior to the 2.1% (13 of 626 patients; 95% con

184 iled to demonstrate that the 16-week regimen was noninferior to the 24-week regimen.

185 , 90.8 microg/mL; GMT, 1114.8; %4 x R, 97.7) was noninferior to the 4-SQ group (GMC, 105.1 microg/mL;

186 the 62.1% treatment success in the CD group was noninferior to the 71.0% in the iHT group (differenc

187 PA by LTA for prasugrel 5 mg in LBW patients was noninferior to the 75th percentile for prasugrel 10

188 he thin-strut sirolimus-eluting Orsiro stent was noninferior to the biolimus-eluting Nobori stent in

189 ion in the extended-release naltrexone group was noninferior to the buprenorphine-naloxone group (dif

190 he every 12 weeks regimen of zoledronic acid was noninferior to the every 4 weeks regimen for the pro

191 udin (provisional GP IIb/IIIa blockade 7.2%) was noninferior to the heparin group for both primary an

192 The everolimus stent was noninferior to the paclitaxel stent for target vesse

193 The rate of MACCE (7.3%) was noninferior to the performance goal (18.3%, pnoninfe

194 The respiratory polygraphy protocol was noninferior to the polysomnography protocol based on

195 gle-blind randomized trial, a novel PtCr-EES was noninferior to the predicate CoCr-EES for TLF, with

196 eks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in pati

197 A(H1N1) during 2012-2013 (the HD formulation was noninferior to the SD formulation for influenza A[H1

198 tients with coronary artery disease, the EES was noninferior to the SES at 9 months.

199 The drug-coated balloon was noninferior to the standard balloon with respect to

200 QIV was noninferior to the TIVs for shared strains (A/H3N2 a

201 The use of high-flow nasal cannulae was noninferior to the use of nasal CPAP, with treatment

202 At month 7, all groups were noninferior to the licensed regimen for all end poi

203 BP, 0.908; SAFIRE 3, 0.935; SAFIRE 4, 0.924) were noninferior to the mean AUC with full-dose FBP scan

204 1 and 2 each had high rates of SVR12, which were noninferior to the reported rate of response to the

205 shown that antibody responses after 2 doses are noninferior to those after 3 doses, suggesting that

206 -16 and HPV-18 one month after the last dose were noninferior to those among young women who received

207 Diagnoses from WSI were noninferior to those from TM.

208 Antibody responses to HPV-6, 11, 16, and 18 were noninferior to those generated by the qHPV vaccine.

209 LBN 0.024% QD in the evening was noninferior to timolol 0.5% BID over 3 months of tre

210 aseline intraocular pressure (P < .001), and was noninferior to timolol in the per-protocol populatio

211 A single dose of oritavancin was noninferior to twice-daily vancomycin administered f

212 TC was noninferior to UC on all primary outcomes.

213 118 groups versus UFH demonstrated that M118 was noninferior to UFH at preventing percutaneous corona

214 3 trials (003 and 004) showed fidaxomicin to be noninferior to vancomycin for curing Clostridium diff

215 It has been found to be noninferior to vancomycin; however, its cost-effectiv

216 In 2 phase 3 clinical trials, telavancin was noninferior to vancomycin in patients with HAP due t

217 WC2031 was noninferior to Vibramycin for uncomplicated urogenit

218 study met the primary efficacy end point of being noninferior to warfarin therapy for the prevention

219 Rivaroxaban is noninferior to warfarin for preventing stroke in atri

220 In this trial, LAA occlusion was noninferior to warfarin for ischemic stroke preventi

221 s major bleeding; and rivaroxaban 20 mg Q.D. was noninferior to warfarin for stroke and systemic embo

222 dage closure with a filter device (Watchman) was noninferior to warfarin for stroke prevention in atr

223 NVAF), left atrial appendage (LAA) occlusion was noninferior to warfarin for stroke prevention, but a

224 Atrial Fibrillation (ROCKET AF), rivaroxaban was noninferior to warfarin for the prevention of stroke

225 tients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke

226 as designed to determine whether rivaroxaban was noninferior to warfarin for the primary end point of

227 superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and sys

228 rction 48), the factor Xa inhibitor edoxaban was noninferior to warfarin in preventing stroke or syst

229 arge randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or syst

230 Dabigatran etexilate 110 mg BID was noninferior to warfarin in reducing stroke and syste

231 The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Dail

232 e (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy.

233 Edoxaban was noninferior to warfarin with respect to the primary

234 actor Xa inhibitor with 50% renal clearance, was noninferior to well-managed warfarin for stroke or s

235 O-SES was noninferior to X-EES for the primary end point (0.10

236 Resolute ZES were noninferior to Xience V EES in treating "real-world

237 Denosumab was noninferior to ZA in delaying time to first on-study

238 zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 w

239 amine whether zoledronic acid every 12 weeks was noninferior to zoledronic acid every 4 weeks in pati